It is noteworthy that the whole PMS cohort did not show significant responses to either IGF-1 or hGH, supporting the preclinical stratification of the patients to identify the ones that might manifest the best or worst responses to the exposure to these compounds. The gene discussed is GH1; the disease is premenstrual tension.